• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

March 19, 2021 By Sean Whooley

Updated Janssen logoJohnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment.

Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, according to a news release.

Janssen’s touts its drug as capable of offering MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy. It’s also proven to have a strong safety profile, the company said.

In a two-year, head-to-head Phase 3 clinical trial, Ponvory (20mg) proved to have superior efficacy in significantly reducing annual relapses by 30.5% when compared to teriflunomide (Aubagio) (14mg) in patients with relapsing MS. In total, 71% of Ponvory patients had no confirmed relapses, compared to 61% in the teriflunomide group.

Additionally, Ponvory slightly edged teriflunomide in reducing the number of new gadolinium-enhancing T1 lesions and the number of new or enlarging T2 lesions (59% and 56%, respectively). Ponvory prevented disability from worsening in nine of 10 patients at three months, too.

Ponvory leaves the blood within one week if treatment needs to be stopped, Janssen said, while effects on the immune system wear off in one to two weeks for most patients. That can offer flexibility in treatment management for patients who need to receive vaccines, address potential infections or begin family planning. There are no known food restrictions and there is no required genetic testing or first-dose monitoring for most patients taking Ponvory.

“Every person with multiple sclerosis is affected differently, given variability in both the underlying disease and emerging symptoms. Continued innovation in this space is critical, and we’re committed to meeting patients’ evolving healthcare needs,” Janssen R&D global head Dr. Mathai Mammen said in the release. “We are proud to offer Ponvory as a valuable new option for people with MS that may help them gain better control of their disease.”

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS